18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study

This publication has 30 references indexed in Scilit:

• Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
  Breast Cancer Research and Treatment, 2024
• Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
  The Lancet Oncology, 2021
• A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
  Breast Cancer Research and Treatment, 2020
• Role of 18F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy
  Clinical Breast Cancer, 2018
• Textural features of 18F-FDG PET after two cycles of neoadjuvant chemotherapy can predict pCR in patients with locally advanced breast cancer
  Annals of Nuclear Medicine, 2017
• Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients
  European Journal of Nuclear Medicine and Molecular Imaging, 2017
• Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
  The Lancet Oncology, 2014
• FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
  The Breast, 2013
• HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
  British Journal of Cancer, 2013
• [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
  European Journal of Nuclear Medicine and Molecular Imaging, 2007